Heartbeat: therapeutic targets for prevention of calcific aortic valve stenosis

doi:10.1136/heartjnl-2020-318014

Catherine M Otto

Current management of calcific aortic valve stenosis (CAVS) is limited to palliation of end-stage disease with valve replacement to relieve left ventricular outflow obstruction. Rather than treating the mechanical consequences of severe CAVS, identification of causal disease pathways at the tissue level might lead to medical therapies that could actually prevent or delay the pathological changes in the valve leaflets. Serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity are associated with the presence of CAVS; however, it has been unclear whether this association is due to a cause–effect relationship. In this issue of *Heart*, Perrot and colleagues¹ used genetic association studies from eight cohorts to show that CAVS was not associated with any of four single nucleotide polymorphisms that are associated with Lp-PLA2 activity or mass. These findings suggest that although Lp-PLA2 activity is a biomarker for CAVS unfortunately, it is unlikely to be a therapeutic target (figure 1).

In an editorial, Zheng and Dweck² discuss this article, summarise current ongoing trials of medical therapy for CAVS (table 1) and comment: ‘Strong evidence points towards elevated Lp(a) levels and its associated oxidised phospholipids (OxPL) as causal risk factors for CAVS, suggesting that targeting this lipid-driven, inflammatory pathway has a real chance to translate into therapy capable of mitigating disease. The current study suggests that this association is not mediated by Lp-PLA2 and underlines the importance of scrutinising whether biological factors within pathophysiological pathways are merely biomarkers or actually represent a feasible and causal target.’

Rheumatic heart disease (RHD) remains the primary cause of valve disease worldwide and contributes significantly to maternal and fetal morbidity and mortality. In a study by Baghel and colleagues³ of 681 pregnant women with RHD, adverse cardiovascular events occurred in about 15% of pregnancies. Multivariable

predictors of adverse outcomes during pregnancy were prior adverse cardiovascular events, lack of appropriate medical

therapy, severity of mitral stenosis, valve replacement and pulmonary hypertension. Based on this analysis, the authors propose

Figure 1 Higher Lp-PLA2 activity is significantly associated with the presence of CAVS in patients with heart disease, but variants influencing Lp-PLA2 mass or activity are not associated with CAVS in this large genetic association study. CAVS, calcific aortic valve stenosis; Lp-PLA2, lipoprotein-associated phospholipase A2.

Table 1 Ongoing randomised clinical trials of medical therapies in aortic stenosis

Study	Target	Treatment
Lipid-driven inflammation pathways		
PCSK9 inhibitors in the progression of aortic stenosis (NCT03051360)	ApoB-containing lipoproteins; PCSK9.	Biweekly injection of PCSK9 inhibitor versus placebo.
EaVaLL—Early Aortic Valve Lipoprotein (a) Lowering (NCT02109614)	Lipoprotein(a).	Daily extended-release niacin 1500–2000 mg versus placebo.
Calcification pathways		
SALTIRE II—Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis (NCT02132026)	Mineral metabolism.	▶ Alendronic acid (n=50) versus placebo tablets (n=25). ▶ Denosumab (n=50) versus placebo injections (n=25).
BASIK2—Bicuspid Aortic Valve Stenosis and the Effect of vitamin K2 on Calcium metabolism on 18F-NaF PET/MRI (NCT02917525)	Vitamin K2–Matrix Gla protein.	Daily vitamin K2 360 µg (n=22) versus placebo (n=22).

Table 2 New prognostic score (DEVI's score) to predict composite adverse cardiac outcome in pregnant women with rheumatic valvular heart disease

Predictor	Score
Prior cardiovascular event*	+4.0
Pulmonary hypertension	+4.0
Taking cardiac medications	–1.0
Severe mitral stenosis	+4.0
Moderate mitral stenosis	+2.0
Mild mitral stenosis	+1.0
Prosthetic heart valve	+2.0

Score is calculated by adding the individual score for the presence of each parameter and its range (minimum–maximum) is 0–12. A score of 5 or more is associated with high risk of adverse cardiac outcome.

*Prior cardiovascular events defined as the occurrence of one or more of the following: heart failure arrhythmia, infective endocarditis and thromboembolic events.

DEVI's Score, aDverse cardiac Events in Valvular rheumatic heart disease In pregnancy.

Correspondence to Professor Catherine M Otto, Division of Cardiology, University of Washington, Seattle, WA 98195, USA; cotto@uw.edu

Figure 2 Left ventricular global longitudinal strain to differentiate between mutation-positive sarcomeric hypertrophic cardiomyopathy and cardiac amyloidosis. (A) Apical four-chamber view of a 66-year-old patient known with mutation-positive hypertrophic cardiomyopathy. The thickness of the septum was 28 mm and the left ventricular ejection fraction was 55%. (B) The polar map shows markedly impaired longitudinal strain in the septal mid and basal areas and the global longitudinal strain is impaired (−13.6%). (C) Apical four-chamber view of a 75-year-old patient diagnosed with light chain amyloidosis. There is concentric hypertrophy of the left ventricle and the ejection fraction is 56%. Based on speckle tracking echocardiography analysis, the left ventricular global longitudinal strain is impaired (−12.2%), with typical sparing of the longitudinal strain values in the apical segments (D). ANT, anterior; ANT SEPT, antero-septal; GS, global strain; INF, inferior; LAT, lateral; POST, posterior; SEPT, septal.

a risk score from pregnant women with RHD (table 2).

Commenting on this paper, Elkayam and Shmueli⁴ point out that in about one-fourth of women, the diagnosis of RHD was not known prior to pregnancy and that a late diagnosis often was

associated with adverse outcomes. Their editorial provides a concise summary of optimal management of pregnant women with RHD. They conclude ‘With proper evaluation and risk stratification prior to pregnancy, a close multidisciplinary follow-up during pregnancy,

and close monitoring during labour and delivery as well as the early post-partum period most complications can be prevented.’

The importance of psychosocial factors in cardiovascular disease (CVD) prevalence and outcomes is increasingly recognised. Using data from the English Longitudinal Study of Ageing, Bu and colleagues⁵ found that loneliness was associated with CVD, independent of possible confounders and other risk factors, with a 30% higher risk of a new CVD diagnosis in the most lonely people compared with the least lonely people. As O’Keefe and colleagues⁶ point out, this data is especially important now in the context of social distancing and stay-at-home recommendations and they offer several approaches to mitigating loneliness during the COVID-19 pandemic.

The *Education in Heart* article⁷ in this issue focuses on the clinical use and prognostic implications of echocardiographic speckle tracking measurements of global longitudinal strain to detect and quantify early systolic dysfunction of the left ventricle (figure 2).

Our *Cardiology-in-Focus* article by Hudson and Pettit⁸ provides a clear-eyed but brief discussion and outstanding graphic of the challenges in reconciling the varying definitions of the ‘normal’ values for left ventricular ejection fraction, as stated in different guidelines (figure 3).

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Otto CM. *Heart* 2020;**106**:1369–1371.

Heart 2020;**106**:1369–1371.
doi:10.1136/heartjnl-2020-318014

ORCID iD

Catherine M Otto <http://orcid.org/0000-0002-0527-9392>

REFERENCES

- Perrot N, Thériault S, Rigade S, *et al*. Lipoprotein-associated phospholipase A2 activity, genetics

Figure 3 Categories of left ventricular ejection fraction. EF, ejection fraction; HF, heart failure; LVEF, left ventricular ejection fraction.

- and calcific aortic valve stenosis in humans. *Heart* 2020;106:1407–12.
- 2 Zheng KH, Dweck MR. Quest for pharmacotherapy in aortic valve stenosis: the lipid hypothesis. *Heart* 2020;106:1376–7.
 - 3 Baghel J, Keepanasseril A, Pillai AA, *et al.* Prediction of adverse cardiac events in pregnant women with valvular rheumatic heart disease. *Heart* 2020;106:1400–6.
 - 4 Elkayam U, Shmueli H. Pregnancy in women with rheumatic valve disease: how to improve the outcome? *Heart* 2020;106:1374–5.
 - 5 Bu F, Zaninotto P, Fancourt D. Longitudinal associations between loneliness, social isolation and cardiovascular events. *Heart* 2020;106:1394–9.
 - 6 O’Keefe JH, O’Keefe EL, Baklanov DV, *et al.* Healing the suffering of the Lonely heart. *Heart* 2020;106:1372–3.
 - 7 Abou R, van der Bijl P, Bax JJ, *et al.* Global longitudinal strain: clinical use and prognostic implications in contemporary practice. *Heart* 2020;106:1438–44.
 - 8 Hudson S, Pettit S. What is ‘normal’ left ventricular ejection fraction? *Heart* 2020;106:1445–6.